The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tandem Diabetes Care, Inc. (“Tandem” or “the Company”) (NASDAQ: TNDM) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Tandem admitted on August 7, 2025, that some of its insulin pumps had a malfunction that could "trigger an error resulting in a discontinuation of insulin delivery," which in turn "could result in hyperglycemia due to discontinuation of insulin delivery" and "may require hospitalization or intervention from a medical professional." The Company stated it sent notices to impacted customers in late July. Based on this news, shares of Tandem dropped over the next several trading sessions.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250921657545/en/